Asuragen Publishes Details about miRNA Pancreatic Cancer Test, Stresses Importance of Validation Process
April 21, 2011
Asuragen Publishes Details about miRNA Pancreatic Cancer Test, Stresses Importance of Validation Process
In a recent paper, Asuragen researchers described the miRNAs measured by the test and discussed its accuracy in distinguishing pancreatic cancer from chronic pancreatitis.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Asuragen Sets Sights on Pancreatic Cancer Screen Through TGen Collaboration
April 22, 2010 / Gene Silencing News - Asuragen Launches FNA Version of microRNA Pancreatic Cancer Diagnostic
February 23, 2012 / Gene Silencing News - Asuragen Presents Data on miRNA Tests for Pancreatic Cancer
November 10, 2011 / Gene Silencing News - TGen to Partner with Asuragen on Cancer Dx
April 16, 2010 / GenomeWeb Daily News - Asuragen Forms Collaborations to Develop FNA Version of Pancreatic Cancer miRNA Test
February 4, 2010 / Gene Silencing News